Canadian Solar Inc. (NASDAQ:CSIQ), maker of solar module products, said its Canadian Solar Solutions subsidiary was hired to supply 4 megawatts of stationary on-grid bulk energy storage, reactive power, voltage support, and bulk energy storage services for the Ontario grid. Canadian Solar will also provide operations and maintenance for a period of 36 months. The 4-megawatt project by the Independent Electricity System Operator will provide an energy storage solution for ancillary services applications in Ontario. Canadian Solar Inc. (NASDAQ:CSIQ) is trading within a 52-week range of $21.38 - $44.50.Click here for a free comprehensive Trend Analysis ReportInovio Pharmaceuticals Inc (NASDAQ:INO) announced a narrower Q3 loss from the same period a year ago on revenues that decreased and missed analyst estimates. The company reported a Q3 loss of $0.12 per share, narrower than the loss of $0.64 per share in 2013 and narrower than the loss of $0.14 predicted by analysts. Total revenues of $1.84 million were down from $9.48 million in Q3 2013 and missed analyst projections of $5.58. The decrease in revenue for the comparable periods was primarily due to the large up-front payment associated with the partnership agreement concluded with Roche in 3Q 2013. Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) are at $11.23 within a 52-week range of $6.80 - $15.80.Click here for a free comprehensive Trend Analysis ReportAldeyra Therapeutics Inc (NASDAQ:ALDX) climbed over 3% Monday morning even as the company reported a Q3 net loss that was wider than the $0.32 per share estimate of one analyst. The biotechnology firm specialized in developing treatments for diseases related to free aldehydes said Q3 net losses attributable to shareholders totaled $2.0 million, or $0.36 per share, compared to net income of $878,000, equal to a diluted net loss of $9.81 per share in Q3 2013. Aldeyra's net income and losses were impacted by the changing nature of the fair market value of its derivative liabilities consisting of convertible preferred stock, preferred stock rights and rights option liabilities. In connection with Aldeyra's initial public offering, all of the preferred stock derivative instruments were converted into Aldeyra's common stock in May 2014.Aldeyra Therapeutics Inc (NASDAQ:ALDX) President and CEO Todd Brady said the company expects to file investigational drug applications for clinical testing of its lead product candidate, NS2, designed to treat Sjogren-Larsson Syndrome and acute anterior uveitis. Brady said the company is on track to start clinical trials on NS2 in the near term, with data expected in 2015. ALDX was up 3.1% at $7.34 in recent morning trade, within a 52-week range of $3.00-$11.99.Click here for a free comprehensive Trend Analysis Report
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
